A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Therapeutic Use
- 03 Jul 2019 Status changed from not yet recruiting to recruiting.
- 21 May 2019 Planned initiation date changed from 1 May 2019 to 1 Aug 2019.
- 12 Feb 2019 Planned End Date changed from 1 Feb 2024 to 1 May 2024.